newsfilter
← Latest News
GlobeNewswire·

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its